Continuous Subcutaneous Apomorphine Infusion for Parkinson Disease Motor Fluctuations: Long-term Data from the Ongoing InfusON Extension Study (P11-5.027)
Evaluate outcomes (up to 3 years) from the ongoing Extension Period of the InfusON study (NCT02339064) of continuous subcutaneous apomorphine infusion (CSAI).
Authors
- Peter A. LeWitt (ORCID: https://orcid.org/0000-0002-4976-4445)
- Alberto J. Espay (ORCID: https://orcid.org/0000-0002-3389-136X)
- Andrea E. Formella (ORCID: https://orcid.org/0000-0003-2737-7898)
- Stuart Isaacson (ORCID: https://orcid.org/0000-0002-9914-5706)
- Gianpiera Ceresoli‐Borroni (ORCID: https://orcid.org/0000-0002-0642-5259)
- S Delgado Reyes
Institutions
- Quest Clinical Research (United States) (US)
- Parkinson's Research and Education Foundation (US)
- Supernus Pharmaceuticals (United States) (US)
- University of Cincinnati (US)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000211288
- Primary Topic
- Neurological disorders and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00